Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs.

Our focus

We are focusing on the development of treatments for neuromuscular and pulmonary diseases that currently lack treatment options, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF).

We have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases. We are passionate about improving patients’ quality of life and our vision is to be a leader in providing treatments for rare diseases in these areas with high unmet medical needs.

Meet our Board of Directors

Elmar Schnee

Chairman of the Board and Member of the Audit and Compensation Committees

Read more

​Philipp Gutzwiller

Board Member and Chairman of the Audit Committee

Read more

Thomas Meier

Founder, Board Member and Chairman of the Scientific Committee

Read more

Patrick Vink

Board Member, Chairman of the Compensation Committee and Member of the Scientific Committee

Read more

Meet our Executive Management team

Stephanie Brown

President North America

Read more

Günther Metz

Head Business Development, EVP

Read more

Oliver Strub

General Counsel & Secretary to the Board, EVP

Read more